Proteomics International is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins.
Proteomics International’s business model is centred on the commercialisation of the the Company’s ground-breaking test for Diabetic Kidney Disease, PromarkerD, whilst using its Promarker platform to create novel diagnostic tests. The Company’s Analytical Services synergistically underpin its research, development and commercialisation activities.
Proteomics International was established in 2001, and is now recognised as a global leader in the field of proteomics. It operates from state-of-the art facilities at the Harry Perkins Institute of Medical Research in Perth, Western Australia.
Proteomics is the large-scale mapping of the structure and function of proteins.